-
Innovation Ranking
NewInnovation Ranking – ACI Worldwide Inc
ACI Worldwide Inc (ACI) offers real-time electronic payment and banking solutions. The company develops, markets, installs, and supports software products and services related to electronic payments. It offers services and solutions to bank, merchants, intermediaries, and billers globally, which utilizes third party digital payment processors, payment associations, switch interchanges, and wide range of automated teller machines (ATM), merchant point-of sale (POS) terminals, bank branches, mobile phones, tablets, corporations, and internet commerce sites. ACI provides its products and services to the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-35030 in Tauopathies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-35030 in Tauopathies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACI-35030 in Tauopathies Drug Details: ACI-35.030 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-35030 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-35030 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ACI-35030 in Alzheimer's Disease Drug Details: ACI-35.030 is under development for the...
-
Product Insights
NewNet Present Value Model: AC Immune SA’s ACI-35
Empower your strategies with our Net Present Value Model: AC Immune SA's ACI-35 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Company Insights
Innovation and Patenting activity of ACI Worldwide Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of ACI Worldwide Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ACI-7104 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ACI-7104 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.ACI-7104 in Parkinson's Disease Drug Details:PD-01 (PD-01A) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Distal Symmetric Polyneuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Distal Symmetric Polyneuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Distal Symmetric Polyneuropathy Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Diabetic Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Diabetic Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Diabetic Neuropathic Pain Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Relapsed Multiple Myeloma Drug Details: Ricolinostat (ACY-1215) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ricolinostat in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ricolinostat in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ricolinostat in Refractory Multiple Myeloma Drug Details: Ricolinostat (ACY-1215) is under...